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The use of neutralizing antibodies to identify the most effective
antigen has been proposed as a strategy to design vaccines
capable of eliciting protective B-cell immunity. In this study, we
analyzed the human antibody response to cytomegalovirus (hu-
man cytomegalovirus, HCMV) infection and found that antibodies
to glycoprotein (g)B, a surface glycoprotein that has been devel-
oped as a HCMV vaccine, were primarily nonneutralizing. In con-
trast, most of the antibodies to the complex formed by gH, gL,
protein (p)UL128, pUL130, and pUL131 (the gHgLpUL128L pen-
tamer) neutralized HCMV infection with high potency. Based on
this analysis, we developed a single polycistronic vector encoding
the five pentamer genes separated by “self-cleaving” 2A peptides
to generate a stably transfected CHO cell line constitutively secret-
ing high levels of recombinant pentamer that displayed the func-
tional antigenic sites targeted by human neutralizing antibodies.
Immunization of mice with the pentamer formulated with differ-
ent adjuvants elicited HCMV neutralizing antibody titers that per-
sisted to high levels over time and that were a hundred- to
thousand-fold higher than those found in individuals that recovered
from primary HCMV infection. Sera from mice immunized with the
pentamer vaccine neutralized infection of both epithelial cells and
fibroblasts and prevented cell-to-cell spread and viral dissemination
from endothelial cells to leukocytes. Neutralizing monoclonal anti-
bodies from immunized mice showed the same potency as human
antibodies and targeted the same as well as additional sites on the
pentamer. These results illustrate with a relevant example a general
and practical approach of analytic vaccinology for the development
of subunit vaccines against complex pathogens.
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Human cytomegalovirus (HCMV) is a ubiquitously distrib-uted member of the Herpesviridae family that establishes
a lifelong infection and represents a major threat for human
health. Primary infection during pregnancy is the most frequent
cause of congenital birth defects, with an overall 0.6% incidence,
whereas severe infections develop in immunocompromised patients
(1, 2). In addition, HCMV has been proposed as an agent associ-
ated with immune senescence (3) and atherosclerosis (4).
HCMV has a broad cell tropism and exploits multiple glyco-
protein complexes present on the virion envelope for binding
and fusion with host cells. Some glycoproteins (g), such as gM/gN
and gB, are used to infect several cell types, whereas glycoprotein
complexes containing gH and gL mediate cell type-specific virus
entry (5, 6). A pentameric complex comprising gH, gL, protein (p)
UL128, pUL130, and pUL131 [gHgLpUL128locus (L)] was shown
to be required by clinical HCMV isolates to infect endothelial,
epithelial, and myeloid cells (7–10). In vitro cultured HCMV viruses
with mutations in the UL128–131 locus lose tropism for endothelial
and epithelial cells but retain the expression of the gHgL-containing
complex, which is sufficient to infect fibroblasts (11).
Because of the high incidence rate of HCMV infections and its
impact on public health, considerable efforts have been made in the
last decade to develop treatments or vaccines capable of preventing
HCMV infection (12). The major target populations for a HCMV
vaccine are seronegative women of childbearing age, whereas
infants represent another potential population contributing to viral
dissemination (13). In addition, patients on a list for organ trans-
plantation (especially those with HCMV-seronegative who are
at risk for life-threatening HCMV disease) would benefit from
a HCMV vaccine. The administration of the HCMV-attenuated
Towne vaccine prevented the development of disease in kidney
transplant recipients, although it did not prevent infection (14).
The abundant virion protein gB was shown to elicit vigorous
T-cell and antibody responses and represents the basis of most
vaccines developed so far (15). However, in recent phase II trials,
a MF59-adjuvanted gB vaccine showed modest efficacy in pre-
venting infection (16) and reducing duration of viremia in
transplant recipients (17). These findings may be explained by
the finding that most antibodies induced by the vaccines lack
virus-neutralizing activity (18), whereas those that neutralized did
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not block efficiently infection of epithelial cells (19). Therefore,
a HCMV vaccine capable of eliciting neutralizing antibodies that
prevent the infection of multiple cellular targets and block viral
dissemination is considered a high priority (20).
Passively administered polyclonal antibodies isolated from
seropositive donors were suggested to be effective in preventing
infection of the fetus (21). These findings were not confirmed in
a recent randomized study where the same antibody preparation
showed a modest, not significant, effect on the rate of congenital
HCMV infection, possibly due to the low level of neutralizing
antibodies contained in Ig preparation (22).
We previously isolated from HCMV immune donors antibodies
that bound to conformational epitopes on the gHgLpUL128L
pentameric complex and were extraordinarily potent in neutral-
izing HCMV infection of epithelial, endothelial, and myeloid cells
(23). The pentamer-specific antibodies neutralized viral infection
at picomolar concentrations and were a thousand-fold more po-
tent than antibodies to gB, gH, or gMgN complex (23). More
recently, we showed that an early antibody response to the pen-
tamer was associated with lack of viral transmission to the fetus
from HCMV-infected pregnant mothers, suggesting that pen-
tamer-specific antibodies are responsible for the inhibition of viral
spread in vivo (24).
In this study, we report a systematic analysis of the human an-
tibody response to HCMV infection, which indicates that the
gHgLpUL128L pentamer is the target of the most effective neu-
tralizing antibodies. Based on this information, we developed
a novel process to produce in a secreted form a recombinant
pentamer vaccine from a mammalian CHO cell line stably trans-
fected by a single polycistronic vector encoding the five different
HCMV pentamer genes separated by autonomous “self-cleaving”
2A peptides. We found that this vaccine can elicit in mice titers of
neutralizing antibodies 100–1,000-fold higher than those induced
by natural infection. These antibodies neutralized infection of
both epithelial cells and fibroblasts and prevented viral dissemi-
nation from endothelial cells to leukocytes.
Results
Analysis of the Neutralizing Antibody Response in HCMV-Infected
Donors. To investigate the specificity and properties of the anti-
bodies produced following natural HCMV infection, we immortalized
memory B cells from HCMV-immune donors (25) and tested the
culture supernatants for the presence of antibodies that bound to
HCMV-infected cells or to recombinant gB, gHgL dimer, and
gHgLpUL128L pentamer expressed in HEK293F cells (24) (Fig.
S1). In the four donors analyzed, the frequency of memory B cells
producing antibodies that stained HCMV-infected cells ranged
from 1.56–3.89% of total IgG+ B cells (Table 1). However, only
a minor fraction of HCMV-specific IgG antibodies bound to gB,
gHgL dimer, or the gHgLpUL128L pentamer (3.5 ± 1.5%, 1.6 ±
0.9%, and 2.9 ± 1.4%, respectively). These findings are consistent
with the notion that the majority of the antibodies produced fol-
lowing viral infection are not neutralizing, being directed against
internal, denatured, or postfusion proteins.
We then tested the monoclonal antibodies (mAbs) that bound
to the surface glycoproteins for their capacity to neutralize in-
fection of epithelial cells by the clinical HCMV strain VR1814.
Consistently with a previous report (18), only a minor fraction of
the gB-binding antibodies had neutralizing activity (26.0 ± 12.6%;
range, 15–43%; Table 1). In contrast, a significantly higher pro-
portion of the antibodies to gHgL (59.0 ± 18.6%; range, 40–83%)
and, even more, of the antibodies to gHgLpUL128L (73.0 ± 18.9%;
range, 50–94%) had HCMV-neutralizing activity. These findings
indicate that following natural HCMV infection a large proportion
of the antibodies produced are not neutralizing and that, among the
target of neutralizing antibodies, the HCMV pentamer stands out
as the antigen that preferentially elicits neutralizing over non-
neutralizing antibodies. Consequently, the antipentamer response
can be defined as having a high “specific activity.”
Analysis of the Antibody Response in Mice Immunized with gB, gHgL,
and gHgLpUL128L Pentamer. To test whether the same hierarchy of
immunogenicity found in naturally infected individuals could be
observed following immunization with recombinant proteins, we
immunized mice with soluble recombinant gB, gHgL dimer, or
gHgLpUL128L pentamer. BALB/c mice were immunized by s.c.
injections of 5 μg of proteins in 0.5% carbopol polymer, boosted
after 2 and 4 wk with soluble proteins, and sera were analyzed on
day 40. The carbopol adjuvant was chosen for its ability to pre-
serve native protein conformation (26). Immunization with sol-
uble gB induced serum antibodies that bound to gB, with an
average ED50 of 10
3.9, and neutralized HCMV infection of epi-
thelial cells and fibroblasts, with an average ID50 of 10
3.5 and
102.2, respectively (Fig. 1 A and D). The difference in neutral-
izing titers reflects the different susceptibility to HCMV in-
fection of epithelial cells versus fibroblasts. Immunization with
soluble gHgL dimer induced serum antibodies that bound to
gHgL and gHgLpUL128L (with ED50 of 10
2.7 and 103.4) and
neutralized infection of epithelial cells and fibroblasts in the
same range as gB-induced antibodies (ID50 of 10
3.5 and 102.7,
respectively) (Fig. 1 B–D). Remarkably, the gHgLpUL128L
pentamer induced antibodies that bound to the dimer as well as
the pentamer (ED50 of 10
3.1 and 103.9) and showed much
higher neutralizing activity, with an ID50 of 10
5.8 on epithelial
cells and 103.9 on fibroblasts (Fig. 1 B–D).
To determine the specific activity of the antibody response
induced by soluble gB or gHgLpUL128L pentamer, we charac-
terized mAbs isolated from immunized mice. A total of 378 gB-
binding mAbs and 246 pentamer-binding mAbs were obtained
from four gB-immunized and four pentamer-immunized mice,
respectively (Fig. S2 A and B). Similarly to that observed with
human mAbs isolated from HCMV-infected donors, only a mi-
nor fraction of gB-specific mAbs (19.9 ± 4.2%) neutralized virus
infection. In contrast, most of the pentamer-specific mAbs
(75.7 ± 11.5%) showed neutralizing activity (Fig. S2A). Neu-
tralizing mAbs displayed a broad range of OD values in ELISA,
comparable to those of mAbs that bound but did not neutralize
(Fig. S2B), indicating that neutralizing activity does not correlate
with high binding. Interestingly, a large fraction (67%) of mAbs
induced by immunization with the pentamer recognized epitopes
present on the gHgL dimer and neutralized infection of both
epithelial cells and fibroblasts, with IC80 values in the nanomolar
Table 1. Antigenic specificity and neutralizing activity of human
mAbs produced by IgG+ memory B cells of HCMV-immune
donors
Antibody
specificity Donor
bAbs/total
Abs, % nAbs/bAbs, n nAbs/bAbs, %
HCMV cells* 1 1.91 6/55 11
2 2.11 7/61 11
3 3.89 32/112 26
4 1.56 7/45 16
gB† 1 0.090 2/13 15
2 0.118 3/17 18
3 0.201 8/29 28
4 0.049 3/7 43
gHgL† 1 0.055 5/8 63
2 0.035 2/5 40
3 0.125 15/18 83
4 0.027 2/4 50
gHgLpUL128L† 1 0.083 6/12 50
2 0.111 13/16 81
3 0.229 31/33 94
4 0.042 4/6 67
bAb, binding antibody; nAb, neutralizing antibody.
*HCMV-positive antibodies were identified by staining of HCMV-infected cells.
†Antibodies specific for gB, gHgL, and gHgLpUL128L were identified by
ELISA using recombinant glycoproteins.
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range (0.08–1.5 μg/mL) (Fig. S2C and Table 2). In contrast, the
remaining mAbs neutralized infection of epithelial cells but not
fibroblasts, but were much more potent, displaying IC80 values in
the picomolar range (0.0001–0.08 μg/mL). A subset of the latter
antibodies was mapped by staining cells transfected with various
combinations of the pentamer subunits and by cross-competition
with human mAbs of known epitope specificity (23) (Table 2).
Interestingly, the low-potency mAbs that neutralized infection of
both epithelial cells and fibroblasts bound to at least two non-
overlapping sites on gH, whereas the highly potent mAbs that
specifically neutralized epithelial cell infection targeted five
previously described sites targeted by human antibodies on the
pentamer (sites 1, 2, 3, 5, and 7) plus at least one additional site.
Taken together, the above analysis performed at the clonal level
reveals a striking parallel between the antibody response of
infected individuals and that of mice immunized with recombi-
nant proteins. In both cases, the gHgLpUL128L pentamer shows
the highest capacity to elicit potent neutralizing antibodies that
inhibit infection of different cell types.
Production of a Soluble gHgLpUL128L Pentamer by CHO Cells Stably
Transfected with a Single Polycistronic Vector. To produce a soluble
gHgLpUL128L pentameric complex that could be developed as
a candidate HCMV vaccine, we designed a single polycistronic
vector encoding five genes (gH, gL, UL128, UL130, and UL131),
each separated by self-cleaving 2A peptides (27). This system was
designed to achieve a stoichiometric production of the five
subunits for an efficient assembly of the pentameric complex.
CHOK1-SV cells were stably transfected with the polycistronic
vector, and a high-producer clone, named CHO-K1SV-5mer,
was selected after two rounds of subcloning. This clone pro-
duced, under laboratory scale, batch conditions in protein-free
chemically defined medium up to 50 mg/L of pentamer. The
preparation of purified, tag-free, soluble pentamer was mono-
disperse with no signs of aggregation (Fig. S3 A and B). The
pentamer was mainly alpha helical, as assessed by circular di-
chroism (CD), and showed good thermal stability (Tm ∼60 °C)
(Fig. S3 C and D). The correct folding and display of relevant
antigenic sites was confirmed by sandwich ELISA, using a panel
of human mAbs targeting eight distinct conformational epitopes
on the HCMV glycoproteins (23) (Table S1).
To assess the immunogenicity of the pentamer produced by
the CHO-K1SV-5mer clone, we immunized mice with different
doses of the pentamer formulated in Ribi, a TLR4-based adjuvant,
which is equivalent to the AS01 adjuvant approved for human use
(28). High serum binding and neutralizing titers were detected in
mice immunized with 5 and 2.5 μg of pentamer, whereas lower
responses were detected in mice immunized with 1 and 0.2 μg
(Fig. 2 A and B). Remarkably, the neutralizing titers against epi-
thelial cells and fibroblasts elicited by the 5 μg dose (IC50 of 106.9
and 104.9, respectively) were ∼16,000- and ∼40,000-fold higher
that those found in the sera of donors 1 mo and ∼1,000- and ∼300-
fold higher that those found 1–2 y after HCMV infection.
To compare the antibody response elicited by immunization of
mice with the pentamer to that of humans infected with HCMV,
we measured the ability of mouse and human sera to inhibit the
binding of a panel of human mAbs targeting four distinct anti-
genic sites on the pentamer (29) (Fig. 2C). This analysis showed
that mouse sera blocked the binding of all of the four antibodies
tested, indicating that the antibody response elicited in mice by
the CHO-derived pentamer is directed against multiple antigenic
sites. The highest titers of antibodies were directed against
pUL128 and gH, a finding that is consistent with the high neu-
tralizing titers directed against both epithelial cells and fibroblasts.
Magnitude and Duration of the Serum Antibodies Elicited by
Different Adjuvants. To determine the optimal adjuvant to be
combined with this antigen, we immunized mice with 2.5 μg of
pentamer formulated with each of the three adjuvants, which
are approved for human use, namely, alum, MF59, and Ribi.
Importantly, the three adjuvants were comparable in their ca-
pacity to elicit serum-neutralizing antibody titers (Fig. 3A).
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Fig. 1. Serum binding and neutralizing titers in mice immunized with gB,
gHgL dimer, or gHgLpUL128L pentamer. Mice were immunized with 5 μg of
HEK293F-produced soluble gB, gHgL dimer, or gHgLpUL128L pentamer in
carbopol 0.5% and boosted on day 14 and 28, and sera were collected on
day 40. (A–C) Inverse IgG serum antibody titers binding (1/ED50) to gB (A),
dimer (B), and pentamer (C) measured by ELISA. Error bars show 95% con-
fidence interval of the geometric mean values. (D) Inverse neutralizing se-
rum antibody titers (1/ID50) measured on epithelial cells (ARPE-19, black
circles) or fibroblasts (MRC-9, white circles).
Table 2. Characterization of mAbs from mice immunized with
soluble pentamer
mAb,
h/m
Neutr,
E/F
LogIC80,
M
Target
antigen*
Competed
hu-mAb†
P25, m E −12.1 pUL128pUL130pUL131 —‡
P40, m E −11.4 pUL128pUL130pUL131 —
P38, m E −11.3 pUL128pUL130pUL131 —
P39, m E −11.2 pUL128pUL130pUL131 —
P53, m E −10.9 pUL128pUL130pUL131 —
P31, m E −10.9 pUL128pUL130pUL131 —
P42, m E −10.6 pUL128pUL130pUL131 8J16
P2, m E −10.8 gHgLpUL128 15D8
P30, m E −10.4 pUL130pUL131 4I22
P37, m E −10.4 gHgLpUL128 15D8
P46, m E −9.5 pUL128pUL130pUL131 4I22
P7, m E −9.5 pUL128pUL130pUL131 —
P16, m E −9.3 pUL128 5A2/8I21
D1, m E+F −9.3 gH 13H11
D7, m E+F −8.9 gH —
D12, m E+F −8.9 gH —
D13, m E+F −8.4 gH —
8J16, h E −12.3 pUL128pUL130pUL131 —
8L13, h E −11.6 pUL130pUL131 —
7I13, h E −11.0 pUL128pUL130pUL131 10P3/15D8
15D8, h E −11.0 pUL128 7I13
10P3, h E −10.5 pUL130pUL131 7I13
5A2, h E −10.0 pUL130pUL131 8I21
8I21, h E −9.5 gHgLpUL128pUL130 5A2
13H11, h E+F −8.6 gH —
Mouse (m) and human (h) mAbs are grouped according to their ability to
neutralize HCMV infection of epithelial cells only (E) or epithelial cells and
fibroblasts (E+F). Shown are the log IC80 values, corresponding to the con-
centration that inhibits 80% infection.
*The target antigens recognized by each antibody were determined using
HEK293T cells transfected with a different combination of HCMV genes, as
previously described (23).
†Cross-competition ELISAs were performed to identify the mouse mAbs that
bound to the same sites recognized by a panel of human mAbs as previously
isolated (23).
‡
“—” indicates that the antibodies recognize novel sites on the pentamer.
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Mice immunized with 2.5 μg of pentamer formulated with either
of the three adjuvants were bled 5 mo after the last immuniza-
tion, and high binding and neutralizing antibody titers were still
present after 5 mo without booster injection (Fig. 3B). There
was a trend for Ribi to be more effective in conferring slightly
higher and more sustained neutralizing antibody responses.
Vaccination with Pentamer Induces a High Level of Dissemination-
Inhibiting Antibodies. To measure the dissemination-inhibiting
activities of the antibodies induced by the pentamer vaccine, the
sera of immunized mice were tested for their ability to block
plaque formation (i.e., cell-to-cell virus spreading) as well as
virus transfer from infected endothelial cells to leukocytes. As
shown in Fig. 4, sera from pentamer-immunized mice displayed
a high potency in both assays, being able to inhibit plaque for-
mation in ARPE-19 cells at dilutions ranging from 103 and 103.5
and HCMV transfer to leukocytes at dilutions ranging from 103.5
and 104.5. These titers are definitely higher than those observed
in human subjects 1 y after infection. Thus, the CHO-derived
pentamer is able to elicit antibodies that block in vitro activities
that well recapitulate the routes of HCMV dissemination in vivo.
Importantly, sera from gB- and gHgL-immunized mice showed
a very weak activity (50% inhibiting titer ≤102) in blocking both
cell-to-cell spreading and virus transfer to leukocytes (Fig. 4).
Collectively, these results indicate that the CHO-derived pen-
tamer is a very potent vaccine that induces antibodies that target
multiple sites, protect different cellular targets, and inhibit me-
chanisms of virus spreading.
Discussion
In this study, we provide an example of a general approach to
vaccine design that starts from the analysis of the human neu-
tralizing antibody response elicited by the pathogen to identify,
produce, and formulate a recombinant subunit vaccine capable
of eliciting the most effective antibody response. We have re-
ferred to this process as “analytic vaccinology” (30).
Our work is founded on the original observation that anti-
bodies that bind to the HCMV gHgLpUL128L pentamer are
extremely potent in neutralizing infection of epithelial, endo-
thelial, and myeloid cells by clinical HCMV isolates (23). This
observation has been confirmed in three recent studies. The
Merck group characterized the antibody response of rabbits
vaccinated with an experimental HCMV vaccine virus in which
the expression of the pentamer complex was restored and
reported that the most potent neutralizing antibodies elicited by
the vaccine were specific for the pentamer and not for gB (31).
Diamond and coworkers reported that a modified vaccinia
Ankara vector expressing rhesus gHgLpUL128L could reduce
viral titers following intradermal challenge with rhesus CMV
(32). More recently, the Novartis group tested in mice the im-
munogenicity of gHgL dimers and gHgLpUL128L pentamers
administered as viral replicon particles or as proteins with MF59
and found that the pentamer induced higher serum antibodies
compared with the dimer with 1/ID50 values of 0.5–2 × 10
5 on
ARPE-19 and 103 on MRC-9 (33).
In this study, we engineered a soluble pentamer produced by
stably transfected CHO cells and found that mice immunized
with this vaccine produced HCMV neutralizing antibodies at
titers that were much higher as compared to previous reports,
i.e., with 1/ID50 > 10
7 on ARPE-19 and 105 on MRC-9. In ad-
dition, we found that all three adjuvants that are licensed for
human use are compatible with the pentamer, with Ribi con-
ferring a slightly higher and more sustained antibody response.
Importantly, the CHO-derived pentamer induced high titers of
antibodies not only against the products of the UL128 locus but
also against gH, as determined by the capacity of the immune
sera to inhibit binding of specific mAbs. These findings explain
the high capacity of the immune sera to neutralize HCMV in-
fection of both epithelial cells and fibroblasts. Moreover, we
found that the immune mouse sera were able to inhibit in vitro
virus spreading in epithelial cells and virus transfer from
endothelial cells to leukocytes, thus showing a potential activity
of the pentamer-elicited antibodies in blocking virus dissemina-
tion in vivo. In conclusion, to the best of our knowledge, we have
produced a vaccine that is able to induce a HCMV-neutral-
izing antibody response of unprecedented potency and breadth,
acting at multiple levels to block HCMV infection.
We have recently shown that in pregnant women infected by
HCMV, the early production of antipentamer antibodies corre-
lates with protection of the fetus, thus providing evidence for an
in vivo protective role of such antibodies (24). The neutralizing
antibody concentration required to block infection in vivo is not
known. However, in several cases, it has been shown that in vivo
protection requires neutralizing titers that exceed by at least 100-
fold the ID90 values (34). It is important to underline that high
titers of neutralizing antibodies are reached only 1–2 y after in-
fection and even not in all patients. It is therefore encouraging to
see that the pentamer vaccine produced in CHO cells can induce
in mice HCMV-neutralizing titers that are 1,000 times higher
than those found in the sera of convalescent donors. Further-
more, although decreasing as expected, neutralizing antibody
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Fig. 2. Binding and neutralizing antibody titers in mice immunized with
different doses of pentamer produced in CHO cells. (A) Binding antibody
titers to gHgLpUL128L pentamer measured by ELISA in the sera of mice
immunized with different doses of pentamer (day 40). Box and whiskers
plot, box containing 50% with median and whiskers minimum to maximum
values. *P < 0.05; **P < 0.01. (B) HCMV-neutralizing titers (1/ID50) of human
sera collected 1 mo or 1–2 y after HCMV infection (Left) and of mouse sera
collected on day 40 (Right) after immunization with the indicated dose of
pentamer in Ribi adjuvant. Neutralization titers were measured on epithelial
cells (black circle) and fibroblasts (white circles). (C) Sera from mice immu-
nized with 5 μg of pentamer in Ribi (black triangles) or from HCMV-infected
donors 1–2 y after infection (white triangles) were tested for their capacity
to inhibit the binding to the pentamer of four human mAb probes that bind
to distinct sites (probes: 15D8, anti-pUL128; 5A2, anti–pUL130pUL131; 8I121,
anti-gHgLpUL128pUL130; 3G16, anti-gH). Shown is the 50% Inhibition of
MAb binding titer (IMAB50).
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titers persist in mouse sera on day 150 at levels at least 50-fold
higher than those found in convalescent donors. Along the same
line, it is tempting to suggest that the modest and uncertain ef-
ficacy of HCMV-immune globulins (22) may be explained by the
insufficient amount of neutralizing antibodies administered.
It is well appreciated that the immune response elicited by live
viruses is dominated by nonneutralizing antibodies, which are
mainly directed against internal proteins or surface proteins in a
denatured or postfusion conformation. Although nonneutralizing
antibodies have been suggested in some systems to contribute to
protection, there is a general consensus that protection requires
neutralizing antibodies that block the interaction of the virus with
its receptors on target cells or that interfere with the virus fusion
machinery (35). Consequently, a desired property of a vaccine is
to elicit an antibody response of high specific activity—that is, to
preferentially induce neutralizing over nonneutralizing antibodies.
The clonal analysis of the antibody response in HCMV-infected
individuals indicates that only a small fraction of HCMV-specific
B cells produces neutralizing antibodies. This low specific activity
is not surprising, in view of the fact that the antiviral response is
known to be directed to a large extent against internal proteins. It
is, however, of interest that the response to surface glycoproteins
has different profiles. We have shown that most pentamer-specific
antibodies produced by infected humans or immunized mice were
neutralizing, indicating that this antigen has the capacity to induce
an antibody response of high specific activity. In contrast, and
consistent with a previous report (18), we found that only a small
fraction of anti-gB antibodies produced have neutralizing activity.
It is tempting to speculate that gB, which is thought to be involved
in the fusion mechanism (36), has a metastable conformation, as
shown for the herpes simplex virus 1 gB (37). Therefore, the low
specific activity of gB-specific antibodies may be due to the fact
that the gB proteins used so far may be in the postfusion confor-
mation, and hence, it is expected to induce mostly nonneutralizing
antibodies, thus limiting the efficacy of current gB constructs as
vaccines. In this case, it would be important to produce a stabilized
prefusion gB, as most neutralizing antibodies are specific for the
prefusion conformation, as recently shown in the case of RSV F
protein (38, 39). In contrast, the pentamer, which functions as
a docking or triggering receptor (40, 41), may not undergo con-
formational changes, explaining why most of the binding anti-
bodies are endowed with neutralizing activity.
In summary, our data suggest that the CHO-derived pentamer
alone, or possibly in combination with a stabilized prefusion form
of gB, represents a promising candidate for a subunit HCMV
vaccine. It is reasonable to hypothesize that vaccines capable of
eliciting an antibody response of high specific activity and able to
limit the spreading of both cell-free and cell-associated virus may
effectively control HCMV infection in immunocompromised
patients and provide sterilizing immunity in healthy individuals.
Materials and Methods
Protein Expression by Transient Transfection of 293F Cells. Intronless full-
length UL128, UL130, UL131, gH (deprived of the transmembrane portion
and the cytoplasmic domains), gL, and gO of VR1814 were cloned into
pcDNA3 vectors (Invitrogen) as previously described (24). Soluble gB was
generated as a truncated ectodomain (amino acids 1–690, accession no.
ACZ79977). The correct reactivity of gB protein was assessed by ELISA using
a panel of neutralizing mAbs previously described (23). Protein purity was
verified by SDS/PAGE followed by SimplyBlue staining (Invitrogen).
Expression of the gHgLpUL128 Pentamer in CHO Cells. To produce a soluble
gHgLpUL128L pentameric complex that could be developed as a candidate
HCMV vaccine, we designed a single polycistronic vector encoding five genes
(gH, gL, UL128, UL130, and UL131), each separated by self-cleaving 2A
peptides. The gHgL and pUL subunits were cloned, respectively, in pEE6.4
and pEE12.4 vectors (Lonza Biologics). Additional modifications were added
to optimize the secretion and purification of the pentamer. The signal
peptide of gH was replaced by an IgG leader sequence (MGWSCIILFLVA-
TATGVHS), and a TEV protease sequence followed by two Strep-Tag was
added downstream of UL131 (ENLYFQGSGSGWSHPQFEKGSGSWSHPQFEK).
The CHO stable cell line secreting the HCMV pentamer was generated by
nucleofection of the vector encoding for the five subunits of the pentamer
into the CHO-K1SV line (GS-System, Lonza). For protein expression, CHO cells
were seeded at 1 × 106/mL in ProCho5 (Lonza); after 10 d, supernatants were
harvested and loaded on affinity column StrepTactin II (Qiagen). Strep-Tag
was removed by treatment with the TEV protease. Protease and uncleaved
proteins were removed by negative chromatography. Finally, proteins were
further purified by size-exclusion chromatography (Superdex 200 from
GE Healthcare).
Protein Characterization. Protein purity and identity was verified by SDS/PAGE
followed by coomassie staining or transferred on a PVDF (polyvinylidene
difluoride) membrane, which was then incubated with antibodies against gB,
gH, gL, pUL128, pUL130, or pUL131. Antibody binding was detected with an
anti-human or anti-rabbit HRP-conjugated antibody (Sigma) in combination
with the enhanced chemiluminescence Western blotting detection reagent
(GE Healthcare). CD experiments were performed as described (38).
ELISA.Antibodies to gB, dimer, or pentamer were measured using a sandwich
ELISA as described (24). To measure the amount of serum antibodies directed
against a particular site, we used a competitive ELISA as described (29).
Briefly, plates with captured recombinant proteins were incubated with
serial dilutions of human or mouse serum followed by biotinylated mAbs of
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Fig. 3. Persistence of neutralizing antibodies in mice immunized with
pentamer produced in CHO cells and formulated with different adjuvants.
Neutralizing antibody titers measured on epithelial cells (black circles) and
fibroblasts (white circles) in the sera of mice collected on day 40 (A) or 150 (B)
after immunization with 2.5 μg of pentamer formulated with Ribi, Alum, or
MF59. Box and whiskers plot, box containing 50% with median and whiskers
minimum to maximum values.
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Fig. 4. Sera from pentamer-immunized mice block HCMV cell-to-cell spreading
in epithelial cells and virus transfer from infected endothelial cells to leukocytes.
Serum titers inhibiting plaque formation (i.e., cell-to-cell virus spreading) in
ARPE-19 cells (A) and HCMV transfer to leukocytes from infected endothelial
cells (B). Mouse sera (white circles) were collected on day 40 following immu-
nization with 5 μg of soluble gB, dimer, or pentamer. Shown are also sera from
five donors collected 1–2 y after onset of HCMV infection (white triangles). Error
bars show 95% confidence interval of the geometric mean values.
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known specificity that were used as probes (23). The amount of probe bound
was quantified using alkaline phosphatase-conjugated streptavidin.
Viral Neutralization, Cell-to-Cell Spreading, and Leukocyte Transfer. Confluent
layers of ARPE-19 or MRC-9 cells in 96-well plates were infected with virus
(MOI of 1) premixed with serial dilutions of mouse serum (inactivated for 20
min at 56 °C). After 40 h, infection was detected using an anti-p72 mAb, and
data were acquired using an automated immunofluorescence imaging sys-
tem (BD Pathway Bioimaging System) as described (23). A plaque inhibition
assay on ARPE-19 that had adsorbed HCMV was used to measure cell-to-cell
spread as previously described (29, 42). To measure inhibition of HCMV
transfer to leukocytes, monolayers of VR1814-infected HUVEC (24-well
microplates 96 h p.i.) were incubated with serial dilutions of immune sera for
2 h at 37 °C followed by addition of leukocytes (29, 42). After overnight
coculture, the leukocytes were fixed, permeabilized, and stained with a pool
of pp65-specific murine mAbs, and the titer resulting in 50% reduction of
pp65-positive leukocytes was calculated.
Human Memory B-Cell Immortalization and Screening. Peripheral blood was
obtained after informed consent from patients 1 mo and 1–2 y after primary
HCMV infection. IgG+ memory B cells were isolated and immortalized by
EBV and CpG as described, and supernatants were screened using both
binding and neutralization assays (25).
Vaccination and Serological Analysis. Carbopol 974P NF polymer was kindly
provided by Lubrizol Advanced Materials. Gel (2% wt/vol) was prepared
from carbopol powder in endotoxin-free H2O, neutralized to pH 7.2–7.4
with 10 M NaOH, and stored at –20 °C until use. Alum Hydroxide (Sigma),
MF59 (Addavax, Invivogen), and RIBI base (Sigma Adjuvant System, Sigma)
were used according to the manufacturer’s instruction. Female BALB/c
mice 6–9 wk of age were obtained from Harlan Laboratories Inc. All pro-
cedures were performed in accordance with guidelines of the Swiss Fed-
eral Veterinary Office and after obtaining local ethical approval. Mice
were immunized s.c. into flank with 100 μL of immunogen formulation on
day 0, 14, and 28. Mice were bled on day 40 and 150, and antigen- and site-
specific IgG titers were measured in the serum by sandwich and competitive
ELISA. Neutralizing titers were also determined on ARPE-19 and MRC-9 cells. In
some experiments, hybridomas were isolated from immune mice according to
standard methods, and the mAbs were characterized for binding and neu-
tralization as described above.
Statistical Analysis. Data were analyzed with Prism 5 (GraphPad Software)
using the two-tailed nonparametric Mann–Whitney U test for comparison of
two groups or Kruskall–Wallis test (and Dunn’s posttest) when three or more
groups were compared.
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